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Acute myeloid leukemia (AML) is an aggressive hematologic malignancy. Hematopoietic cell 
transplantation (HCT) is used to treat AML, but the chemotherapy and total body irradiation used in 
pre-transplant regimens are associated with high treatment related toxicity. Many patients suffer 
relapse of disease after HCT, suggesting the pre-transplant regimens do not adequately eliminate all 
cancerous cells. To selectively kill leukemic cells before transplant, radioimmunotherapy (RIT) 
delivers targeted doses of radiation by conjugating radionuclides to antibodies that recognize cell 
surface antigens on leukemic cells. The majority of RIT studies have used antibodies labeled with 
beta-emitting radionuclides. However, alpha-emitting radionuclides have higher decay energies and 
shorter path lengths, only 50-80 microns, equivalent to a few cell diameters. Using alpha-emitters for 
RIT has the potential to increase the radiation delivered to leukemic cells and decrease the off target 
killing of normal cells and tissues. 
Only a few alpha-emitters are suitable for RIT, including Astatine-211 (
211
At), and their usage is 
limited by availability, in vivo stability, and labeling chemistry. In a recent study published in Blood, 
Drs. Johnnie Orozco, Oliver Press, John Pagel and colleagues in the Clinical Research Division 
studied the efficacy and toxicity of 
211
At conjugated to an anti-CD45 antibody in a mouse model of 
AML. CD45 is a cell surface antigen expressed on hematopoietic cells, with limited expression on 
other tissues, and has been used as a target for RIT for AML. In conjunction with Radiation 
Oncology at the University of Washington, a novel method for labeling antibodies with 
211
At was 
used to prevent uncoupling of the radionuclide from the antibody in vivo. 
To determine if the antibody delivers radiation specifically to hematopoietic cells, the researchers 
first examined the biodistribution of radiation delivered throughout the body after injecting mice 
with 
211




At localized to tissues rich in 
hematopoietic cells, the bone marrow and spleen, with less uptake in other organs, which was 
confirmed by alpha imaging (see figure). Then to assess the therapeutic efficacy of 
211
At-B10-30F11, 
the researchers used a clinically relevant disseminated murine myeloid leukemia model. The 
leukemic mice showed an improvement in median overall survival when treated with 12 microcurie 
(μCi)211At-B10-30F11compare to 211At-labeled control antibody (69 days vs. 54 days, p=0.0003), but 
both improved survival over untreated mice (36 days, p<0.0001). Higher doses of radiation, 24 μCi 
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211At-B10-30F11, resulted in non-leukemic death for 70% of mice due to killing of normal 
hematopoietic cells in the bone marrow and subsequent infection. The mice still had normal kidney 
and liver function. 
The researchers then evaluated whether 
211
At-B10-30F11 treatment followed by bone marrow 
transplant would improve outcomes in the mouse model. A dose-dependent improvement in median 
overall survival was observed for mice treated with 12, 20, or 24 μCi 211At-B10-30F11 (OS of 61, 
101, and 123 days (p<0.001)) compared to untreated (37 days) or 
211
At-labeled control antibody 
treated mice (46.5 days, p=0.0023) followed by bone marrow transplant. Importantly, bone marrow 
transplant reconstituted the immune systems of the mice improving survival over 24 μCi 211At-B10-
30F11 treatment alone (see figure). Furthermore, toxicity studies only showed transient 
myelosuppression after treatment that fully recovered within four weeks, with no impact on kidney or 
liver function.  
"Historically, increasing radiation or chemotherapy dose may decrease relapse rates, but the added 
toxicity negates any potential survival benefit," according to Dr. Orozco in regards to pre-transplant 
conditioning regimens for AML.  "Our new studies show that with CD45 targeting, we can 
dramatically escalate radiation doses to CD45+ hematopoietic target tissues by virtue of the 
significantly higher decay energies of alpha-emitters over other radionuclides previously studied, 
largely beta- and gamma-emitters that have lower decay energies by one or two orders of 
magnitude." Future clinical trials are warranted to study if this RIT strategy can improve outcomes in 
human AML patients post transplant. 
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Image modified from manuscript with authors’ permission. 
Anti-CD45 radioimmunotherapy targets alpha-emitting radiation 
to hematopoietic organs and prolongs survival in a murine 
myeloid leukemia model. Alpha camera imaging confirms 
targeting of radiation to mouse spleen (A) and femur (C) three 
hours after intravenous injection of 211-At-labeled anti-CD45 
antibody (B10-30F11), with quantitative histograms displayed to 
the right of the respective organs (B, D). Improved survival 
curves with increasing doses of 211-At-B10-30F11 compared to 
control antibodies prior to hematopoietic stem cell transplant in a 
murine myeloid leukemia model (E). 
 
